glp-1 news today cardiovascular outcomes 2025 november studies add to growing body of evidence demonstrating significant benefit on Cardiovascular Effects and Tolerability of
Description
Achieve your health goals
Unfortunately, no significant differences were noted between the groups on other parts of the MDS-UPDRS during the on medication state, or in other secondary assessments relating to e.g
See the pooled clinical-trial evidence here
5 2
Our team is also working on the next wave of medicines, including a non-incretin injection weight loss drug called eloralintide that is related to an old medicine called pramlintide
